Development of myelodysplasia (MDS) with subsequent progression t o acute myeloid leukemia (AML) is an example of the multistep process of malignant transformation in which each step often relates t o genetic abnormalities that can be directly seen as chromosomal aberrations. Therapyrelated MDS and AML (t-MDS and t-AML) may serve as an ideal model for a study of the genetic evolution of MDS and AML because chromosomal abnormalities are observed in most cases and because the disease is often diagnosed early due t o a close patient follow-up. The cytogenetic characteristics at diagnosis were studied in 137 consecutive cases o f t -MDS and t-AML, including 22 new cases, and correlated with the clinical characteristics and the course of the disease. Balanced translocations t o chromosome bands 11q23 and 21q22 represent primary steps in pathways leading directly t o overt t-AML. Specific chromosomal deletions or losses, on the other hand, represent primary or secondary events in alternative pathways leading t o t-MDS with potential for subsequent transformation t o overt t-AML. Loss of a whole chromosome 7 (-7) or deletion of its long arm (7q-I and deletion of the long arm of a chromosome 5 (5q-) were the most frequent primary abnormalities significantly re-OTH MALIGNANT transformation and tumor progression are the consequences of multiple genetic changes leading to an increased proliferation or a decreased apoptosis and thereby to clonal expansion. The various genetic abnormalities often result from specific chromosomal aberrations that may be present in all malignant cells at diagnosis. The sequence of genetic changes leading to malignant transformation has previously been discussed in detail for various solid tumors including colorectal cancer' and Wilms' tumor.' Myelodysplasia (MDS) and acute myeloid leukemia (AML) are malignancies of the hematopoietic stem cell and may be observed as independent entities. However, the two diseases often share chromosomal characteristic^,"^ intermediate stages are frequently observed, and patients presenting with MDS often subsequently transform to overt AML, representing a clinical example of the multistep model for malignant transformation.' For this reason it could be of major interest to study the type and sequence of genetic changes Loss of a whole chromosome 5 (-5) was also a primary event, but surprisingly, was observed equally in t-MDS and in t-AML. Deletion of chromosome 13, including bands q13q14, was another less common primary aberration of t-MDS. Except for -7 and dellltq), these primary aberrations were most often observed together with secondary abnormalities. These included balanced aberrations involving band 3q26 and various deletions of chromosome 3, a gain of a whole chromosome 8, deletions of the short arm or loss of chromosomes 12 and 17, loss of a whole chromosome 18, and deletions of the short arm of chromosome 21. Deletions or loss of chromosomes 5 and 7 were significantly associated with previous therapy with alkylating agents ( P = .002), and balanced translocations t o chromosome bands 3q26, llq23, and 21q22 were significantly associated with previous therapy with drugs targeting DNAtopoisomerase II ( P < .00005). Other characteristic aberrations were not related t o any specific type of therapy. The molecular changes believed t o contribute to the development of t-MDS and t-AML have been identified for many of these chromosomal abnormalities. leading to development of MDS and overt AML with and without preceding MDS.
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Most cases of MDS and AML arise de novo without knowledge of the causative factors. In such patients the early stages of MDS are often overlooked, and up to half of these cases have a normal kary~type.~.~ However, during recent years, 10% to 20% of all new cases of MDS and AML observed in many major institutions are found to arise in patients previously treated with irradiation or chemotherapy for other malignancies or a systemic disease. [6] [7] [8] In most instances, there is a close hematologic follow-up after such therapy, so that t-MDS or t-AML, if they arise, are diagnosed at an early stage. In addition, approximately 85% to 90% of these patients present characteristic clonal chromosomal abnormalities of the same types as observed in de novo MDS and AML."l2 Therefore, a study of the cytogenetic abnormalities of t-MDS and t-AML in relation to the clinical course of the disease could be of specific interest and provide more information about the molecular events that lead to the development of MDS and AML in general.
The present study reports detailed clinical and cytogenetic data for our most recent 22 patients at diagnosis of t-MDS and t-AML and includes a reanalysis of 1 15 previously published cases.'* The aim was to identify those steps in the multistep development of t-AML, to which the different unbalanced and balanced chromosomal aberrations relate. Furthermore, based on the new cases, to reanalyze the relationship between types of previous therapy and specific chromosomal abnormalities, now including balanced aberrations of band 3q26, and to reanalyze the patients' response to intensive antileukemic chemotherapy.
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AML such as refractory, unexplained cytopenia or leukocytosis at the follow-up after previous chemotherapy or radiotherapy for other malignant or systemic diseases, were candidates for cytologic and cytogenetic examination of the blood and the bone marrow (BM). For many years patients have been studied regardless of t y p of primary disease, and even cases with an end-stage primary tumor and BM involvement have been investigated. During the period 1976 through 1994, 155 consecutive cases of t-MDS and t-AML were identified in this way" including our most recent 22 previously unpublished cases. This analysis includes the most recent 137 cases in which the karyotypes were examined by banding technique.
In all patients, cytology was studied on cells obtained from the peripheral blood and the BM after May-Grunewald-Giemsa staining and standard cytochemical reactions. These results were compared with the immunologic characteristics as observed by fluorescenceactivated cell sorting analysis of Ficoll-Isopaque-isolated mononuclear cells using a panel of specific monoclonal antibodies.
Overt t-AML was subclassified according to the French-American-British n0menc1ature.l~ t-MDS was not subclassified, mainly because of technical problems with many poor preparations and an often hypoplastic and fibrotic BM.
Cytogenetic investigations were performed on BM aspirates from the iliac crest using the GTL-banding technique after a 1-to Cday culture. The results were expressed in accordance with the International System for Human Cytogenetic Nomenclature (ISCN 1991).14 Fluorescence in situ hybridization (FISH) studies were performed in the same manner as described previo~sly'~ using cosmid contigs for the AMLl gene.
Frequently observed chromosomal aberrations and chromosomal aberrations observed in at least two cases as the only abnormality present were in this study classified as primary changes. All other chromosomal aberrations were classified as secondary changes. Abnormalities associated with development of t-MDS were classified as early changes, whereas aberrations associated with overt t-AML were classified as late changes.
RESULTS
New series of 22 cases of t-MDS and t-AML.
During the period 1992 through 1994, we observed a further 22 cases of t-MDS or t-AML (Table 1) . Thirteen patients had received alkylating agents, five patients had received various agents targeting DNA-topoisomerase I1 (A'ITOP) and 11 patients had received high-voltage radiotherapy, administered in 4 as the sole type of therapy. One patient had received '"I for thyroid cancer (case 153) and one patient had received chemotherapy for ovarian cancer with platinum derivatives only (case 142). Seventeen patients presented with t"DS, five with overt t-AML.
Chromosomal abnormalities were observed in 20 patients, whereas two had a normal karyotype. Nine patients had lost a whole chromosome 7, five patients a whole chromosome 5, four patients had lost various parts of the long arm of a chromosome 7, and four patients various parts of the long arm of chromosome 5. Six patients had balanced chromosomal abnormalities, in two cases involving band 1 lq23 and in two other cases band 3q26. Two patients for whom clinical and cytogenetic data have been published previously,'6 were reanalyzed by FISH. This investigation disclosed a t(3;21)(q26;q22) in case 69 and a t(1;21)(p36;q22) in case 70.
Chromosomal abnormalities at diagnosis in relation to clinical presentation of the disease. In our entire series of 137 patients, eighteen presented an apparently normal karyotype, 46 patients presented one single chromosomal abnormality and 73 patients presented multiple chromosomal aberrations at diagnosis (Table 2) . Sixty-six patients presented with t-MDS and did not progress to leukemia, most dying from cytopenic complications or progression of the primary tumor. Eight remain alive and are being followed. Twenty-eight patients presented with t-MDS and subsequently transformed to overt t-AML, whereas 43 patients presented with overt t-AML without preceding t-MDS (Table 2). A normal karyotype at diagnosis was significantly related to clinical presentation with overt t-AML because it was observed in 12 of 43 patients presenting as t-AML, compared with only 6 of 94 patients presenting with t-MDS ( P = .002) ( Table 3) .
A single clonal chromosomal abnormality was observed in 46 cases in our entire series (Table 4 ). Of these, the most frequently observed abnormality was loss of a whole chromosome 7 (-7), found in 20 patients. Eighteen of these 20 patients presented with t-MDS and only 4 progressed to overt t-AML. Twelve patients had only one balanced translocation in all cases involving chromosome bands llq23 or 21q22. Eleven of these 12 patients presented with overt t-AML. One case presented as refractory anaemia with excess of blasts, but transformed to overt t-AML after only 4 months. Three of the 46 patients had deletions of the long arm of a chromosome 7 (7q-), three patients had deletions of the long arm of a chromosome 13 (1 3q-) and two patients had deletions of the long arm of a chromosome 5 (5q-) ( Table 4 ). All of these patients presented with t-MDS. Six patients had various different single clonal chromosomal abnormalities, as listed in Table 4 .
All cytogenetic abnormalities observed at diagnosis in the 94 patients presenting with t-MDS are shown on Fig 1. In t-MDS, unbalanced aberrations predominate with loss of whole chromosomes 5 and 7 or various parts of their long arms. In addition, various deletions are common, both of the long and the short arms of chromosome 3 and of the short arm of chromosomes 12, 17, and 21. Nonrandom abnormalities also include loss of a whole chromosome 17 or 18. Only a few balanced aberrations are observed, primarily three cases of t(3;21) and two cases with other balanced aberrations involving chromosome band 3q26.
In 43 patients presenting with overt t-AML, on the other hand (Fig 2) , balanced translocations predominate involving the long arm of chromosomes 8, 11, and 21 and the short arm of chromosomes 9 and 19. Loss of a whole chromosome 7 or deletions of its long arm are also observed, but far less frequently than in cases presenting with t-MDS. In this series, deletions of the long arm of chromosome 5, deletions or loss of chromosome 3 and deletions of the short arm of chromosome 12 are not observed at all in patients presenting with overt t-AML.
Specific unbalanced chromosomal abnormalities observed. The most frequently observed unbalanced aberrations in our entire series of 137 patients were loss of a whole chromosome 7 or deletions of various parts of its long arm (Table 3) . Eight patients had lost the whole long arm, in seven because of an unbalanced translocation: der(7) t(1;7) (qlO;plO), another eight patients had deletions with breakpoint at 7q22 and three with breakpoint at 7q32. Deletions of the long arm or loss of chromosome 7 were both significantly associated with presentation as myelodysplasia. Deletions of the long arm of chromosome 5 were also significantly related to and only observed in cases presenting with t-MDS ( Table 3 ). The deletions included loss of the entire long arm in three patients caused by unbalanced translocations. In all 20 patients, bands q22 through q31 were missing. Loss of a whole chromosome 5, on the other hand, was observed as frequently in cases presenting with t-MDS as in cases presenting as overt t-AML. Deletions of the short and long arms and loss of a whole chromosome 3 were observed only in patients presenting with t-MDS. Also deletions of the short arm of chromosome 12 (always including band p13) were observed exclusively in patients presenting with t-MDS.
A gain of a chromosome 8, various deletions of the short arm or loss of a whole chromosome 17, loss of a whole chromosome 18, and loss of various parts of the short arm of a chromosome 21, were all observed to the same degree in patients presenting with t-MDS as with overt t-AML (Table 3). The deletions of the short arm of chromosome 17 included band p13 in all 1 1 patients. The dcletions of the short arm of chromosome 21 included deletion of the whole shorl arm bccnuse of an isochromosome i(21q) or unbalanced trnnslocations with chromosomes S, 13, or IS in five cases, whereas three patients presentcd other unbalanced translocations, all with an apparent loss of bands 2 1~1 2 and SpeciJiic halarlccd chromosotnal uhnormali~ies rhserved.
Balanced chromosomal aberrations were observed in 22 of a lotal of I37 palients ( Table S ) . Ten cases had balanced translocations to chromosome hand I 1~123, eight cases had balanccd translocations to chromosome band 2 I q22, and five cases had balanced aberrations involving chromosome band 3q26. Only rwo cases, 134 and 154, presented balanced translocations not involving any of these three bands, and i n case 154, the t( I O ; 12) was observed only in a subclone.
Among 18 patients with balanced trmslocations to bands I lq23 and 21q22, fourteen patients prcsented with overt t-AML and one had a short phase of t-I\/IDS beflre transforming to overt t-AML. Three patients with a t(3;21), one patient with t(3; 17), and one patient with inv(3) a l l had an additional deletion of part of the long arm o r lo\s of a whole chromosome 7 and presented with t-MDS of longer duration. Only thc patient with t(3;17) subsequently transformed to overt t-AML. Of I O patients wilh balanced translocations to chl-olnosonx band I lq23, an additional chromosomc aberration was obser\/ed in only 1 patient. This was a deletion o f the long arm of a chromosome X in a subclone, whereas five of eighL patients with balanced aberrations to chromosome band 21q22 also had deletions of the long arm of chromosome 7 o r loss 01 the whole chromoson~e.
21p13.
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Cytogenetic abnormalities related to type of previous therapy. The relationships between the most important cytogenetic subgroups of t-MDS and t-AML and types of therapy for the primary tumor for all 137 patients are shown on Table 6 . For patients with deletions or loss of chromosomes 5 or 7, a highly significant association was observed to previous therapy with alkylating agents with or without drugs targeting DNA-topoisomerase I1 compared with other types of therapy. In 20 patients with balanced translocations to chromosome bands 3q26, llq23, or 21q22, all but 2 had received at least one of the cytostatic drugs etoposide, doxorubicin, 4-epi-doxorubicin, or mitoxantrone, all targeting DNA-topoisomerase I1 (Table 5) , also a highly significant association. In these calculations, platinum derivatives were not considered to be classical alkylating agents, and patients with balanced aberrations to chromosome bands 3q26 and 21q22 were classified according to these abnormalities, despite an additional deletion or loss of a chromosome 5 or 7 in some cases.
Response to intensive antileukemic chemotherapy. The response to intensive antileukemic chemotherapy in 43 patients with overt leukemia (in most cases comprising 3 days' daunorubicin or another antracycline combined with 7 days continuous infusion of cytosine arabinoside) is shown in Table 7 . Complete remission, although often of short duration, was obtained in 22 patients. Most predictive for obtaining complete remission was presentation of the disease as overt leukemia ( P = ,016). Although the difference was not significant, patients with deletion or loss of chromosomes S or 7 apparently responded poorly to intensive chemotherapy as compared with patients with balanced chromosome aberrations.
Dzfferent cytogenetic pathways for the development of t-MDS and overt t-AML. The findings in our total series of 137 patients suggest that the multistep development of t-MDS and t-AML may follow alternative genetic pathways associated with specific chromosomal aberrations. Some of the cytogenetic and genetic abnormalities must be assumed to be primary changes of importance for development of the disease, whereas other abnormalities are more likely secondary changes, often involved in progression of the disease (Fig 3) .
Primary and early abnormalities significantly associated with t-MDS were loss of a whole chromosome 7 or deletions of various parts of its long arm, deletions of various parts of the long arm of a chromosome S, and deletions of chromosome bands 13(q13q14) (Fig 3) . Because it occurs frequently, loss of a whole chromosome S must also be supposed to represent a primary aberration. However, interestingly, it appears to be associated with a later stage of the disease because it was observed to the exact same degree in t-MDS and overt t-AML and always associated with other abnormalities. Primary and late abnormalities significantly related to presentation as overt t-AML, and thereby representing different pathways in leukemogenesis, included the various balanced translocations to chromosome bands 1 lq23 and 21q22, except for t(3;21).
Secondary abnormalities in early stage disease, observed only in cases presenting as t-MDS, included balanced chromosomal aberrations involving band 3q26, deletions of the short or the long arm or loss of a whole chromosome 3, and deletions of the short arm of chromosome 12 (Fig 3) . These chromosomal abnormalities were never observed as the sole aberration. Secondary abnormalities in later stage disease, because they were observed to the same degree in t-MDS and overt t-AML, included gain of a whole chromosome 8, loss of a whole chromosome I 7 or various parts o f its short arm, loss of a whole chromosome 18 and deletions of the short arm of a chromosome 2 I (Fig 3) . Except for one single case, the unbalanced secondary abnormalities were observed exclusively in patients who showed deletion or loss of chromosomes S and 7 as primary abnormalities, and were not observed in patients presenting balanced translocations to chromosome bands I lq23 and 21q22. A simultaneous deletion or loss of chromosomes S or 7 was observed in all four cases with balanced aberrations of band 3q26, in five of eight cases with balanced aberrations of band 21q22, but in none of IO cases with balanced aberrations of 1 lq2.3 (Table S ) .
DISCUSSION
In our new series of 22 patients with t-MDS and t-AML, patient 136 with Hodgkin's disease, previously treated repeatedly with radiotherapy and subsequently with MOPP, developed t-MDS with a normal karyotype only 12 months after the start of chemotherapy. After a further 8 months, the disease transformed to overt t-AML, and at that time, an inv(16)(p13q22) was observed as an evolutionary chromosomal abnormality. This is the first case of t-AML we have observed with this aberration, inv( 16) being a characteristic and not uncommon abnormality in AML de-novo.' A recent review of the effects of cisplatinum emphasized that t-MDS or t-AML had never been observed following therapy with cisplatinum alone, except for one case that occurred after local instillation in the urinary bladder." Subsequently, a case of t-AML was described in a patient treated for laryngeal cancer with cisplatinum, S-fluorouracil and radiotherapy.IX To our knowledge, patient 142 is the first reported case of t-MDS after general therapy with platinum derivatives only.
Case 150 is unusual because of BM necrosis at diagnosis, which rendered complete karyotyping impossible. Cases 145 and 146 show the particularly high risk of t-AML with balanced chromosomal translocations after therapy of breast cancer with 4-epi-doxorubicin and cyclophosphamide, previously reported on from our department." It is of interest that patient 146, in addition to a high cumulative dose of 4-epi-doxorubicin (1,000 mg/m2), received ICRF 187, a cardioprotector belonging to the dioxopiperazin derivatives.'" The leukemogenic potential of this group of drugs, some of which have also been shown to target DNA-topoisomerase 11, has been emphasized recently." To our knowledge, case I S 1 is the first case reported of t-MDS after single-agent chemotherapy with tauromustine, a new nitrosourea. Finally, case 153 is our first case of t-AML after therapeutic use of a radioactive isotope.
The genetic pathways for patients presenting with t-MDS and patients presenting with overt t-AML seem to differ markedly, as reflected by divergent chromosomal characteristics (Figs l and 2 ). In general, unbalanced aberrations predominated in patients presenting with t-MDS, whereas balanced translocations to chromosome bands l lq23 and 21q22, except for t(3;21), were observed almost exclusively in patients presenting with overt t-AML. It is a surprising observation that many patients with multiple chromosomal deletions or losses, even involving both chromosomes S and 7, presented with t-MDS like patients with only one of these For personal use only. on October 23, 2017. by guest www.bloodjournal.org From
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aberrations, and did not evolve to overt t-AML (Fig 3) . As far as the balanced chromosome translocations to bands 1 lq23 and 21q22 are concerned, all-except for t(3;21)-must be assumed to exert a strong and direct effect on leukemic transformation. Thus, the balanced translocations were often observed as a sole aberration in patients presenting as overt t-AML. Cytogenetic changes during evolution from t-MDS to t-AML could not be studied more extensively because of a median survival of only 6 months,22 and because many patients refused repeated BM puncture. Previous results from de novo MDS23 and our own limited experience of t-MDS22 have indicated that cytogenetic evolution is observed in only about 25% of patients at transformation from MDS to AML.
In previous studies of t-MDS and t-AML, most attention has been directed toward the loss of whole chromosomes 5 and 7 or deletions of various parts of their long arms. The critical region on the long arm of chromosome 5 that is always deleted is band 5q3 I . 24 A critical region for chromosome 7 is less certain, but it could be band 7q22. 25 The genes of importance located to these bands have not been identified so far, despite extensive research. In de-novo MDS with 5q-it has been suggested that different lengths of the deletions of the long arm of chromosome 5 may relate to different clinical manifestations.26 Our current results, based on 36 patients (Table 3) , suggest an analogous association with 3549 deletions of the long arm of a chromosome 5 observed exclusively in t"DS, whereas loss of a whole chromosome 5 was observed to the exact same degree in t " D S as in overt t-AML. The additional chromosomal aberrations observed in all patients with -5 and in most patients with 5q-did not differ significantly and, thus, could not explain the difference in clinical presentation.
In t-AML (Table 5 ) and AML de novo several different chromosomes may undergo balanced translocations with chromosomes 1 l and 21 with breakage at bands llq23 and 21q22. At chromosome band 1 lq23, the M U gene has been cloned and sequenced27328 and at chromosome band 21q22, the AMLl gene has been cloned and sequenced. 29 In almost all patients with AML and balanced chromosomal translocations involving bands llq23 and 21q22, the MLL and the AMLl genes have been found to undergo chimeric rearrangement with different genes from the various partner chromosomes30 ( Table 8) . Many of the genes involved in these various translocations code for transcription factors3' and may thereby represent master genes32 controlling the expression of several other genes responsible for cellular proliferation and leukemic transformation.
Development of t-MDS or t-AML with deletions or losses of chromosomes 5 and 7 has for many years been associated with previous therapy with alkylating agent^.^"^ More recently, development of t-AML with balanced translocations involving chromosome bands 1 lq23 and 21q22 has been related to preceding therapy with drugs targeting DNA-topoisomerase II,33.34 often in combination with cisplatin or an alkylating agent. The present extended series of patients with t-MDS and t-AML confirms these associations and suggests a new association between balanced aberrations to 3q26, presentation of the disease as t-MDS, and previous therapy with drugs targeting DNA-topoisomerase I1 (Tables 5 and   6 ). A more systematic role has been proposed for DNAtopoisomerase I1 in the development of balanced chromosome translocations in generaL3' The enzyme induces double-strand breaks and rejoining of DNA as a part of its normal function. The epipodophyllotoxins and many anthracyclines specifically inhibit the rejoining, and may thereby facilitate illegitimate mitotic recombination between the broken DNA strands of two different chromosomes.
Deletion of the long arm of chromosome 13, involving band q14, has for a long time been known as a recurring abnormality in patients with myeloid disorders,35 and was observed as the only abnormality in three patients (Table 4) . Loss of a whole chromosome 13 as part of a complex karyotype was observed in an additional four patients. All seven patients had previously been treated with alkylating agents and six presented with t-MDS. The Rb gene, mapped to chromosome band 13q14,36.37 is known to be mutated a n d or deleted at both alleles in retinoblastoma and in some solid tumors. In some cases of AML, the gene was not tran~cribed,'~ whereas it was most often normally transcribed in MDS.39 Although, in the study of AML de novo, absence of transcription was not related to deletion or loss of chromosome 13, but rather related to regulation at the posttranscriptional it seems still possible, in our patients, that loss of the Rb gene, or of another tumor suppressor gene by deletion of chromosome band 13q14, could play a primary role in the development of the disease.
Balanced rearrangements of chromosome band 3q26 were observed in five patients: three with t(3;21), one with inv(3)(q21q26), and one with t(3;17) (q26;q22) ( Table 5 ). Four of these five patients had received a combination of drugs targeting DNA-topoisomerase I1 and an alkylating agent, and all five patients presented with t-MDS, as did most previously reported therapy-related cases with t(3;21 ).4" The EVII gene has been mapped to chromosome band 3q26 and shown in AML to be expressed almost exclusively in cases presenting translocations involving band 3q26.4' Subsequently, the EVII gene together with two other adjacent genes at band 3q26, the MDSI and the EAP, have been shown to be abnormally expressed in patients with t-MDS and t(3;21).42
As far as the other secondary unbalanced chromosomal aberrations are concerned, the critical event in the various deletions of the short arm of chromosome 12 could be deletions of the TEL gene containing a helix-loop-helix domain or a deletion of an adjacent unidentified tumor suppressor gene at 12pl 3. 43 A loss of a whole chromosome 18 results in a loss of many important genes, among which is the DCC gene at band 18q21, known very often to be deleted in colorectal cancer.44 It was suggested recently that deletion and decreased expression of this particular gene could be an important event also in the development of AML. 45 Finally, in about 15% of patients with AML de novo and in a few patients with MDS, p53 gene mutations have been ob~erved.~' This gene is on chromosome band 17p 1 347 and is known to be involved in DNA repair and apoptosis. The gene has been shown to be mutated in many solid tumors. often related to aggressive disease.48 p53 gene mutations were observed predominantly in AML, with deletions of the short arm of chromosome 17 including band p1 3, and in cases with loss of a whole chromosome 17.4h Further research must show more precisely the impact on leukemogenesis of the genetic changes induced by each of the recurrent chromosomal abnormalities in MDS and AML. The involvement of so many different genes in these diseases is striking, and may explain the major variations in the morphology, the clinical presentation, the clinical course and the response to intensive chemotherapy. Activation of dominant oncogenes by balanced chromosomal translocations, and loss of putative tumor suppressor genes or genes for apoptosis by chromosomal deletions or loss of whole chromosomes, seem respectively to have a different impact on leukemic transformation and to follow different genetic pathways. Even so, there may still be additional important genetic abnormalities in the development of MDS and AML that have not shown themselves as visible chromosomal aberrations.
